Market Overview:
The global neuroprotective drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of neurodegenerative diseases, rising geriatric population, and growing awareness about neuroprotective drugs. Based on type, the global neuroprotective drugs market is segmented into cholinesterase inhibitors, anti-inflammatory agents, and others. Cholinesterase inhibitors are expected to account for the largest share of the global neuroprotective drugs market in 2018 owing to their high efficacy in treating Alzheimer’s disease and other neurological disorders. Anti-inflammatory agents are also expected to witness significant growth during the forecast period due to their ability to reduce inflammation and protect neurons from damage. Based on application, the global Neuroprotective Drugs Market is segmented into Alzheimer’s disease, Parkinson’s disease, traumatic brain injury (TBI), stroke, and others (Huntington’s disease).
Product Definition:
Neuroprotective drugs are drugs that protect neurons from damage or death. They are important for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Cholinesterase inhibitors:
Cholinesterase inhibitors are the drugs that inhibit the action of cholinesterase. Cholinesterase is an enzyme responsible for breaking down a chemical called acetylcholine which is important in helping nerve cells to communicate with each other. The most commonly used cholinesterase inhibitors are Donepezil, Exelon, and Neurontin.
Anti-inflammatory:
An anti-inflammatory drug is any pharmaceutical agent that reduces the inflammatory response. The most common symptoms of inflammation are redness, heat, swelling, and pain. Inflammation can be caused by a wide variety of factors such as infections (bacterial or viral), autoimmune diseases (such as rheumatoid arthritis), food additives, and smoking among others.
Application Insights:
The others segment held the largest market share in 2017. This is due to the rising prevalence of neurodegenerative disorders, such as multiple sclerosis, brain cancer and spinal cord injuries. According to a study published by the National Center for Biotechnology Information (NCBI) in 2014, around 60% of all people suffering from neurological disorders are diagnosed after death. Therefore, increasing number of deaths caused by neurological disorders is boosting this segment growth.
Alzheimer¢â‚¬â„¢s disease application was one of the leading segments owing to high prevalence rate and government initiatives encouraging effective treatment for Alzheimer¢â‚¬â„¢s disease globally. For instance, in November 2016 Germany announced a ¢â€š¹100000$ research grant program for promising candidates developing drugs against Alzheimer's disease dementia). Such initiatives are expected to boost regional market growth over next few years.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of pharmaceutical companies and increased R&D expenditure. The region is expected to maintain its dominance over the forecast period due to increasing cases of neurodegenerative diseases, growing geriatric population, and rising healthcare expenditure.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to increasing awareness about potential treatment options for neurodegenerative diseases coupled with government support for medical research & development activities in emerging economies such as India & China. Moreover, an increase in disposable income levels will also boost market growth during this period.
Growth Factors:
- Increasing incidence of neurological disorders: The global prevalence of neurological disorders is increasing at an alarming rate. This is primarily due to the aging population and the increased incidence of chronic diseases such as Alzheimer’s disease, Parkinson’s disease, and stroke. As a result, there is a growing demand for neuroprotective drugs that can help in the treatment or prevention of these conditions.
- Advances in drug discovery and development: The field of neuroprotection has seen significant advances in recent years with the advent of new technologies and approaches for drug discovery and development. This has led to the emergence of novel neuroprotective drugs that are more effective and safer than traditional therapies.
- Growing awareness about neurological disorders: There is a growing awareness among people about various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, etc., Their symptoms, risk factors, and available treatments options. This has led to an increase in demand for neuroprotective drugs worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuroprotective Drugs Market Research Report
By Type
Cholinesterase inhibitors, Anti-inflammatory, Others
By Application
Alzheimer's disease, Parkinson's disease, Others
By Companies
Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Neuroprotective Drugs Market Report Segments:
The global Neuroprotective Drugs market is segmented on the basis of:
Types
Cholinesterase inhibitors, Anti-inflammatory, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alzheimer's disease, Parkinson's disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genervon Biopharmaceuticals (Canada)
- NeuroVive Pharmaceutical (Sweden)
- Ceregene (USA)
- BHRPharma (Thailand)
- Neuren Pharmaceuticals (Australia)
- Allon therapeutics (Canada)
- Bionure Inc. (USA)
Highlights of The Neuroprotective Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cholinesterase inhibitors
- Anti-inflammatory
- Others
- By Application:
- Alzheimer's disease
- Parkinson's disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuroprotective Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuroprotective drugs are medications that protect the brain from damage.
Some of the major players in the neuroprotective drugs market are Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA).
The neuroprotective drugs market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neuroprotective Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neuroprotective Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neuroprotective Drugs Market - Supply Chain
4.5. Global Neuroprotective Drugs Market Forecast
4.5.1. Neuroprotective Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neuroprotective Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neuroprotective Drugs Market Absolute $ Opportunity
5. Global Neuroprotective Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neuroprotective Drugs Market Size and Volume Forecast by Type
5.3.1. Cholinesterase inhibitors
5.3.2. Anti-inflammatory
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neuroprotective Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neuroprotective Drugs Market Size and Volume Forecast by Application
6.3.1. Alzheimer's disease
6.3.2. Parkinson's disease
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neuroprotective Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neuroprotective Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neuroprotective Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neuroprotective Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neuroprotective Drugs Demand Share Forecast, 2019-2029
9. North America Neuroprotective Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neuroprotective Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neuroprotective Drugs Market Size and Volume Forecast by Application
9.4.1. Alzheimer's disease
9.4.2. Parkinson's disease
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neuroprotective Drugs Market Size and Volume Forecast by Type
9.7.1. Cholinesterase inhibitors
9.7.2. Anti-inflammatory
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neuroprotective Drugs Demand Share Forecast, 2019-2029
10. Latin America Neuroprotective Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Application
10.4.1. Alzheimer's disease
10.4.2. Parkinson's disease
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neuroprotective Drugs Market Size and Volume Forecast by Type
10.7.1. Cholinesterase inhibitors
10.7.2. Anti-inflammatory
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neuroprotective Drugs Demand Share Forecast, 2019-2029
11. Europe Neuroprotective Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neuroprotective Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neuroprotective Drugs Market Size and Volume Forecast by Application
11.4.1. Alzheimer's disease
11.4.2. Parkinson's disease
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neuroprotective Drugs Market Size and Volume Forecast by Type
11.7.1. Cholinesterase inhibitors
11.7.2. Anti-inflammatory
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neuroprotective Drugs Demand Share, 2019-2029
12. Asia Pacific Neuroprotective Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Application
12.4.1. Alzheimer's disease
12.4.2. Parkinson's disease
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neuroprotective Drugs Market Size and Volume Forecast by Type
12.7.1. Cholinesterase inhibitors
12.7.2. Anti-inflammatory
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neuroprotective Drugs Demand Share, 2019-2029
13. Middle East & Africa Neuroprotective Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Application
13.4.1. Alzheimer's disease
13.4.2. Parkinson's disease
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neuroprotective Drugs Market Size and Volume Forecast by Type
13.7.1. Cholinesterase inhibitors
13.7.2. Anti-inflammatory
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neuroprotective Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Neuroprotective Drugs Market: Market Share Analysis
14.2. Neuroprotective Drugs Distributors and Customers
14.3. Neuroprotective Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Genervon Biopharmaceuticals (Canada)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. NeuroVive Pharmaceutical (Sweden)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Ceregene (USA)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BHRPharma (Thailand)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Neuren Pharmaceuticals (Australia)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Allon therapeutics (Canada)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bionure Inc. (USA)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
